By reducing neuroinflammation from both the metabolic and the alcohol-related sides, these medications may break the self-reinforcing cycle where inflammation drives consumption, and consumption drives more inflammation
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Recientemente, un ensayo de 26 semanas (ADJUST-T1D) aleatoriz a 72 pacientes con diabetes tipo 1 y obesidad a semaglutida o placebo
For patients using GLP-1 medications to manage Type 2 diabetes, stopping can lead to a rise in blood glucose levels
New Psychotic or Manic Symptoms CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania
GLP-1 Penetration and Demand The market growth of GLP-1 drugs has been driven by the high prevalence and cost burden of obesity and diabetes in the US